• Client Login
Ozmosi
  • Services
    • BEAM Clinical Trial Data
    • GCT Global Clinical Trials
    • PRYZM Pharma Product Database
    • PDUFA Calendar
    • KRYSTL Industry Scan Reporting
    • LENZ Company Pipeline Summary
    • Specialized Consulting
    • Approved Pharmaceutical Products in Use
  • About Us
  • Case Studies
  • Newsroom
  • Contact Us
Select Page
Merck Diabetes Pipeline Analysis

Merck Diabetes Pipeline Analysis

Jun 23, 2025 | Business, Data Analytics, Diabetes, Disease Area Trends

Merck’s two blockbuster diabetes products, Janumet® and Januvia®, are DPP-4 inhibitors that generated nearly $3.3 billion in Sales in 2016.3 Januvia® is especially known for its great cardiovascular safety profile, which has helped differentiate itself in its class....
The Future of Innovation in Diabetes & Heart Disease

The Future of Innovation in Diabetes & Heart Disease

Jun 23, 2025 | Chronic Disease, Diabetes, Disease Area Trends, Heart Disease

When it comes to improving the lives of patients with chronic illnesses like type-2 diabetes and heart disease, the pharmaceutical industry is playing an ever smaller role.  New blockbuster drugs are the lifeblood of pharmaceutical companies.  Traditionally, they...

New Faces in Big Pharma & the Rise of the Billion Dollar Deal

Jun 23, 2025 | Business, Industry Trends

M&A mania is here. Unprecedented deal values for mergers and acquisitions dominated in 2014.  Worldwide M&A was up 47% since 2013 with 95 deals valued greater than $5 billion, as reported by Reuters. Most deals were transacted in the energy,...
Novo Nordisk Diabetes Pipeline Analysis

Novo Nordisk Diabetes Pipeline Analysis

Jun 23, 2025 | Chronic Disease, Diabetes, Disease Area Trends

Novo Nordisk remains a top player in the Diabetes market with blockbuster insulins NovoLog®  and Levemir® which brought in a combined almost $3.5 billion in 20166, Victoza® a GLP-1 that brought in $2.1 billion in 20166, and recently launched Basal insulin/GLP-1...

Pharma Forecasting Case Study – Valuing the Impact of Development Delays

Jun 23, 2025 | Case Study, Case Study Forecasting

A multinational pharmaceutical firm asked Ozmosi to provide forecasts to assess the market impact of delays in delivering new formulation and packaging for an existing product. A planned reformulation seen as necessary to preserving market share had been delayed for...
« Older Entries

Recent Posts

  • Letting the Data Tell the StoryJune 23, 2025
  • Keeping up with the Pharmaceutical Industry in AsiaJune 23, 2025
  • Merck Diabetes Pipeline AnalysisJune 23, 2025
  • The Future of Innovation in Diabetes & Heart DiseaseJune 23, 2025
  • New Faces in Big Pharma & the Rise of the Billion Dollar DealJune 23, 2025
  • Novo Nordisk Diabetes Pipeline AnalysisJune 23, 2025
  • Home
  • About Us
  • Services
  • Case Studies
  • Newsroom
  • Contact Us
  • Facebook
  • X
OZMOSI© 2025 | All Rights Reserved | Site by Webtyde